Page 210 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Chapter 10
REFERENCES
1. Makris NE, Boellaard R, van Lingen A, et al. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab. J Nucl Med. 2015;56:249-254.
2. O’Donoghue JA, Lewis JS, Pandit-Taskar N, et al. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer. J Nucl Med. 2018;59:161- 166.
3. Diagnostiek | RIVM [Internet]. [cited 2019 Feb 22]. Available from: https://www.rivm.nl/medische- stralingstoepassingen/trends-en-stand-van-zaken/diagnostiek
4. Fahey FH, Treves ST, Adelstein SJ. Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med Technol. 2012;40:13-24.
5. ICRP Publication 62. SAGE Publications Ltd [Internet]. [cited 2019 Feb 22]. Available from: https:// uk.sagepub.com/en-gb/eur/icrp-publication-62/book243732.
6. Gebhart G, Lamberts LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619-624.
7. Lodge MA. Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med. 2017;58:523-532.
8. Vet HCW de, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine: A Practical Guide.
Cambridge University Press; 2011.
9. Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, et al. ImmunoPET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors. J Nucl Med. February 2019.
10. Glassman PM, Abuqayyas L, Balthasar JP. Assessments of antibody biodistribution. J Clin Pharmacol. 2015;55 Suppl 3:S29-38.
11. Vugts DJ, Klaver C, Sewing C, et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe- NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno- PET. Eur J Nucl Med Mol Imaging. 2017;44:286-295.
12. Makris NE, Boellaard R, Visser EP, et al. Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med. 2014;55:264-267.
13. Kaalep A, Huisman M, Sera T, et al. Feasibility of PET/CT system performance harmonisation for quantitative multicentre 89Zr studies. EJNMMI Phys. 2018;5:26.
14. Bensch F, Smeenk MM, van Es SC, et al. Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse. Theranostics. 2018;8:4295-4304.
15. Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664.
16. Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852-1858.
17. Waaijer SJH, Warnders FJ, Stienen S, et al. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res. 2018;24:4988-4996.
18. Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. J Nucl Med. 2018;59:3-12.
19. Badawi RD, Shi H, Hu P, et al. FIRST HUMAN IMAGING STUDIES WITH THE EXPLORER TOTAL-BODY PET SCANNER. J Nucl Med. 2019: Epub ahead of print.
20. Veldhuijzen van Zanten SEM, De Witt Hamer PC, van Dongen GAMS. Brain access of monoclonal antibodies as imaged and quantified by 89Zr-antibody-PET: perspectives for treatment of brain diseases. J Nucl Med. February 2019.
21. Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Front Immunol. 2017;8:1804.
208